A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Other
Enrollment
105actual
Sites
10
Country
India
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-06 | actual | When the study began enrolling |
| Primary completion | 2026-06-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-12 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes
Intervention
- Drug: iGlarLixi (insulin glargine/lixisenatide) — also filed as Soliqua®, Solostar®
Primary outcome
what the primary-completion date above is the date OFPercentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs)
measured From Day 1 to Week 25
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed